Auris Medical Holding AG (NASDAQ:EARS) saw a significant increase in short interest in August. As of August 31st, there was short interest totalling 1,146,344 shares, an increase of 64.4% from the August 15th total of 697,127 shares. Based on an average daily volume of 1,833,027 shares, the days-to-cover ratio is presently 0.6 days. Currently, 8.1% of the shares of the company are sold short.
Several institutional investors have recently added to or reduced their stakes in EARS. Advisor Group Inc. purchased a new position in Auris Medical Holding AG during the second quarter valued at $277,000. TFS Capital LLC boosted its position in Auris Medical Holding AG by 17.7% in the second quarter. TFS Capital LLC now owns 38,230 shares of the company’s stock valued at $160,000 after buying an additional 5,762 shares during the last quarter. Finally, Bellevue Group AG purchased a new position in Auris Medical Holding AG during the first quarter valued at $7,897,000. 30.95% of the stock is currently owned by hedge funds and other institutional investors.
Auris Medical Holding AG (NASDAQ:EARS) opened at 1.76 on Friday. The stock’s market capitalization is $60.42 million. The company’s 50-day moving average price is $2.56 and its 200 day moving average price is $3.51. Auris Medical Holding AG has a 52-week low of $1.55 and a 52-week high of $7.96.
Several equities analysts have recently weighed in on the company. Zacks Investment Research cut Auris Medical Holding AG from a “hold” rating to a “sell” rating in a research report on Monday. Needham & Company LLC lifted their price target on Auris Medical Holding AG from $5.00 to $11.00 and gave the company a “buy” rating in a research report on Friday, August 19th. JMP Securities cut Auris Medical Holding AG from an “outperform” rating to a “market perform” rating in a research report on Thursday, August 18th. Leerink Swann restated a “buy” rating and set a $12.00 target price on shares of Auris Medical Holding AG in a research report on Wednesday, June 15th. Finally, Jefferies Group restated a “buy” rating on shares of Auris Medical Holding AG in a research report on Friday, June 10th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $8.88.
Auris Medical Holding AG Company Profile
Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.
Receive News & Ratings for Auris Medical Holding AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical Holding AG and related companies with MarketBeat.com's FREE daily email newsletter.